

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/EP2004/011512

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/62 C07K14/705 C07K14/47 A61K38/17 A61K31/7088

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>NGUYEN P ET AL: "Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes." GENE THERAPY, vol. 10, no. 7, April 2003 (2003-04), pages 594-604, XP002314391 ISSN: 0969-7128 the whole document</p> <p>-----</p> <p>-/--</p>	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

21 January 2005

Date of mailing of the international search report

14/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Schneider, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/011512

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MARQUES ERNESTO T A JR ET AL: "HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 39, 26 September 2003 (2003-09-26), pages 37926-37936, XP002314392 ISSN: 0021-9258 the whole document</p>	
A	<p>WETTSTEIN D A ET AL: "EXPRESSION OF A CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX MHC HETERODIMER IN A LIPID-LINKED FORM WITH ENHANCED PEPTIDE-SOLUBLE MHC COMPLEX FORMATION AT LOW PH" JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, no. 1, 1991, pages 219-228, XP002314393 ISSN: 0022-1007 cited in the application the whole document</p>	
A	<p>WO 02/080851 A (AUGUST THOMAS; MARQUES ERNESTO JR; UNIV JOHNS HOPKINS) 17 October 2002 (2002-10-17) the whole document</p>	
A	<p>US 2002/151707 A1 (DESHPANDE SHRINKANT ET AL) 17 October 2002 (2002-10-17) the whole document</p>	
P,A	<p>MARGALIT A ET AL: "Chimeric beta2 microglobulin/CD3zeta polypeptides expressed in T cells convert MHC class I peptide ligands into T cell activation receptors: A potential tool for specific targeting of pathogenic CD8+ T cells" INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 15, no. 11, November 2003 (2003-11), pages 1379-1387, XP009039662 ISSN: 0953-8178 the whole document</p>	
P,A	<p>WO 2004/015395 A (NAT JEWISH MEDICAL AND RES CT) 19 February 2004 (2004-02-19) the whole document</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/011512

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02080851	A	17-10-2002	CA 2446462 A1	17-10-2002
			EP 1385538 A2	04-02-2004
			WO 02080851 A2	17-10-2002
US 2002151707	A1	17-10-2002	AU 6331696 A	30-12-1996
			CA 2224205 A1	19-12-1996
			EP 0833930 A2	08-04-1998
			JP 11507238 T	29-06-1999
			WO 9640944 A2	19-12-1996
			US 6060309 A	09-05-2000
WO 2004015395	A	19-02-2004	WO 2004015395 A2	19-02-2004
			US 2004110253 A1	10-06-2004